FDA Drug Recalls
411 recalls · Class II, newest first
Class II · Moderate risk Terminated Dec 30, 2024
Reason Presence of Foreign Tablets/Capsules: A Paracetamol 500 mg tablet was found in a 1000-count bottle of Metformin HCL ER Tablets USP, 500 mg.
Class II · Moderate risk Ongoing Dec 30, 2024
Reason CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Class II · Moderate risk Ongoing Dec 30, 2024
Reason CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Class II · Moderate risk Ongoing Dec 30, 2024
Reason CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Class II · Moderate risk Ongoing Dec 27, 2024
Reason Presence of Particulate Matter: A market complaint was received of a glass piece in the vial.
Class II · Moderate risk Ongoing Dec 23, 2024
Reason CGMP Deviations; product intended for quarantine was inadvertently distributed
Class II · Moderate risk Terminated Dec 23, 2024
Reason Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
Class II · Moderate risk Terminated Dec 23, 2024
Reason Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
Class II · Moderate risk Terminated Dec 20, 2024
Reason Failed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term…
Class II · Moderate risk Terminated Dec 19, 2024
Reason Lack of Assurance of Sterility: The tamper-evident seal on several of the syringes are not attached upon receipt of shipment.
Class II · Moderate risk Terminated Dec 19, 2024
Reason Lack of Assurance of Sterility: The tamper-evident seal on several of the syringes are not attached upon receipt of shipment.
Class II · Moderate risk Terminated Dec 18, 2024
Reason Failed Dissolution Specifications: Out of specification observed during the accelerated stability conditions for the 30 count bottles.
Class II · Moderate risk Ongoing Dec 18, 2024
Reason CGMP Deviations
Class II · Moderate risk Terminated Dec 17, 2024
Reason Failed Dissolution Specifications:
Class II · Moderate risk Ongoing Dec 16, 2024
Reason Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle
Class II · Moderate risk Ongoing Dec 13, 2024
Reason Presence of Foreign Tablets/Capsules
Class II · Moderate risk Ongoing Dec 12, 2024
Reason CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
Class II · Moderate risk Ongoing Dec 12, 2024
Reason CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
Class II · Moderate risk Ongoing Dec 11, 2024
Reason CGMP Deviations: N-Nitroso-Desmethyl Chlorpromazine impurity (NNDCI) were found to be failing per current FDA recommended limit.
Class II · Moderate risk Ongoing Dec 11, 2024
Reason CGMP Deviations: N-Nitroso-Desmethyl Chlorpromazine impurity (NNDCI) were found to be failing per current FDA recommended limit.
Class II · Moderate risk Ongoing Dec 10, 2024
Reason Crystallization
Class II · Moderate risk Ongoing Dec 10, 2024
Reason Crystallization
Class II · Moderate risk Terminated Dec 10, 2024
Reason Lack of Sterility Assurance
Class II · Moderate risk Terminated Dec 10, 2024
Reason Lack of Sterility Assurance
Class II · Moderate risk Ongoing Dec 6, 2024
Reason CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.